UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 73

Sortiert nach

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

The New England journal of medicine, 2010-09, Vol.363 (12), p.1117-1127

2010

Volltextzugriff (PDF)

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Blood, 2010-04, Vol.115 (15), p.3109-3117

2010

Volltextzugriff (PDF)

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response

Cancer discovery, 2015-03, Vol.5 (3), p.316-331

2015

Volltextzugriff (PDF)

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

ACS medicinal chemistry letters, 2017-05, Vol.8 (5), p.486-491

2017

Volltextzugriff (PDF)

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

Blood, 2012-10, Vol.120 (17), p.3510-3518

2012

Volltextzugriff (PDF)

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

Blood, 2010-04, Vol.115 (17), p.3520-3530

2010

Volltextzugriff (PDF)

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050

The Journal of immunology (1950), 2010-05, Vol.184 (9), p.5298-5307

2010

Volltextzugriff (PDF)

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors

Molecular cancer therapeutics, 2010-02, Vol.9 (2), p.489-498

2010

Volltextzugriff (PDF)

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

Cancer cell, 2006-07, Vol.10 (1), p.39-50

2006

Volltextzugriff (PDF)

Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation

Journal of investigative dermatology, 2011-09, Vol.131 (9), p.1838-1844

2011

Volltextzugriff (PDF)

Dissecting p53 tumor suppressor functions in vivo

Cancer cell, 2002-04, Vol.1 (3), p.289-298

2002

Volltextzugriff (PDF)

An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo

Nature genetics, 2003-03, Vol.33 (3), p.396-400

2003

Volltextzugriff (PDF)

Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer

Clinical cancer research, 2007-03, Vol.13 (6), p.1892-1902

2007

Volltextzugriff (PDF)

INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support

Neoplasia (New York, N.Y.), 2010-01, Vol.12 (1), p.28-38

2010

Volltextzugriff (PDF)

Loss of p53 Impedes the Antileukemic Response to BCR-ABL Inhibition

Proceedings of the National Academy of Sciences - PNAS, 2006-05, Vol.103 (19), p.7444-7449

2006

Volltextzugriff (PDF)

Control of apoptosis by p53

Oncogene, 2003-12, Vol.22 (56), p.9030-9040

2003

Volltextzugriff (PDF)

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo

Molecular cancer therapeutics, 2009-01, Vol.8 (1), p.26-35

2009

Volltextzugriff (PDF)

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

Clinical cancer research, 2011-11, Vol.17 (22), p.7127-7138

2011

Volltextzugriff (PDF)

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

Nature, 2004-03, Vol.428 (6980), p.332-337

2004

Volltextzugriff (PDF)

Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab

Cancer biology & therapy, 2006-06, Vol.5 (6), p.648-656

2006

Volltextzugriff (PDF)

Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity

Clinical cancer research, 2009-11, Vol.15 (22), p.6891-6900

2009

Volltextzugriff (PDF)

Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model

Journal of medicinal chemistry, 2009-12, Vol.52 (23), p.7364-7367

2009

Volltextzugriff (PDF)

Discovery of a Potent, Selective, and Orally Active Human Epidermal Growth Factor Receptor-2 Sheddase Inhibitor for the Treatment of Cancer

Journal of medicinal chemistry, 2007-02, Vol.50 (4), p.603-606

2007

Volltextzugriff (PDF)

The interplay between inhibition of JAK2 and HSP90

JAK-STAT, 2012-04, Vol.1 (2), p.77-79

2012

Volltextzugriff (PDF)

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

Blood, 2010-04, Vol.115 (14), p.2919-2927

2010

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(72)
Dissertationen
(1)

Sprache

Englisch
(73)
Japanisch
(18)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response

INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation

Dissecting p53 tumor suppressor functions in vivo

An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo

Selective Inhibition of ADAM Metalloproteases as a Novel Approach for Modulating ErbB Pathways in Cancer

INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support

Loss of p53 Impedes the Antileukemic Response to BCR-ABL Inhibition

Control of apoptosis by p53

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab

Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity

Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model

Discovery of a Potent, Selective, and Orally Active Human Epidermal Growth Factor Receptor-2 Sheddase Inhibitor for the Treatment of Cancer

The interplay between inhibition of JAK2 and HSP90

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis

Suchergebnisse filtern